Key result
A high VTE-BLEED score was associated with an increased risk of major bleeding after day 30 compared to a low score (treatment-adjusted HR 2.3; 95% CI 1.1-4.5) in patients with VTE.
Why the study?
Does the VTE-BLEED score predict major bleeding and other adverse events in patients with VTE on chronic anticoagulation?
Cohort (n=4,457)
Yes
Does the VTE-BLEED score predict major bleeding and other adverse events in patients with VTE on chronic anticoagulation?
Hazard Ratio: 2.3 (95% CI 1.1–4.5)
The VTE-BLEED score successfully predicts major bleeding and all-cause mortality in a practice-based cohort of VTE patients on anticoagulation, which may aid in decision-making regarding therapy duration.
No takes yet. Share an insight, caveat, or question.
May aid post-day-30 bleeding risk stratification in VTE; leaves open impact on anticoagulation duration decisions.
Klok et al. (2018) conducted a cohort in Venous thromboembolism (VTE) (n=4,457). High VTE-BLEED score vs. Low VTE-BLEED score was evaluated on Major bleeding after day 30 (HR 2.3, 95% CI 1.1-4.5). A high VTE-BLEED score was associated with an increased risk of major bleeding after day 30 compared to a low score (treatment-adjusted HR 2.3; 95% CI 1.1-4.5) in patients with VTE.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: